GSK, Emergent and Oxford University commence trial of Ebola vaccine candidates

British drugmaker GlaxoSmithKline (GSK), Emergent BioSolutions and the University of Oxford have commenced a new Phase I study of Ebola vaccine candidates.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news